Leadman Biochemistry proceeds with plan to acquire Xiansheng Xiangrui Biological Products

Beijing Leadman Biochemistry Co., Ltd. is proceeding with its plan to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through a cash payment. This transaction is expected to constitute a major asset restructuring, giving Leadman Biochemistry control over the target company and making it a holding subsidiary. The company currently holds no shares in the target company.

On July 30, 2025, the company signed an investment framework agreement with the target company and its shareholders, including Shanghai Baijiahui Investment Management Co., Ltd., Hainan Xiansheng Baijiahui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership). As of the announcement date, due diligence, auditing, and valuation work are ongoing, and no formal transaction documents have been signed by the involved parties.

The company emphasizes that the transaction is still in the planning stages and is subject to the completion of due diligence, auditing, valuation, and necessary internal and external approvals. There remains uncertainty regarding the finalization of the transaction, including potential changes in terms due to external factors or failure to reach an agreement with the counterparty. The company’s stock will not be suspended from trading during this period.